All Articles
HOPA, Bone Marrow & Cancer Foundation, and Walgreens Specialty Unite to Provide Oncology Pharmacy Education
HOPA, the Bone Marrow & Cancer Foundation (BMCF), and Walgreens Specialty Pharmacy have partnered on digital outreach resources and tools to support patients who are navigating the complexities of cancer treatment.
Development and Implementation of Oral Anticancer Agent Tools for a Thematic Quality Improvement Program
The HOPA OCC, with the participation of ASCO Quality Training Programs, has developed practice-based tools to aid in developing and improving initiatives and the care of patients receiving oral anticancer agents (OAAs).
Late-Breaking HOPA News: Fam-trastuzumab deruxtecan-nxki for HER2 Ultralow Metastatic Breast Cancer
The ability of fam-trastuzumab deruxtecan-nxki to treat breast cancer patients with HER2 IHC 0 with positive membrane staining up to IHC 3+ has changed the treatment paradigm for metastatic disease.
Pharmacist's Application to Practice: Zolbetuximab-clzb
Olivia Tholt, PharmD, PGY2 Oncology Pharmacy Resident, and Sarah Cimino, PharmD, BCOP, Clinical Pharmacist Specialist, Gastrointestinal Oncology, both from Vanderbilt University Medical Center, Nashville, TN, write about zolbetuximab-clzb (Vyloy).
Pharmacist's Application to Practice: Sacituzumab govitecan-hziy
Brooke Kielkowski, PharmD, PGY2 Oncology Pharmacy Resident, and Jordan Hill, PharmD, BCOP, Pharmacy Clinical Specialist, both from WVU Medicine - West Virginia University Hospitals, Morgantown, WV, write about sacituzumab govitecan-hziy (Trodelvy).
Pharmacist's Application to Practice: Vorasidenib
Lacy La Fever, PharmD, MS, PGY2 Oncology Pharmacy Resident, and Anastasia Graham, PharmD, MBA, BCOP, Clinical Oncology Specialist, Neuro-oncology, both from Medical University of South Carolina, Charleston, SC, write about vorasidenib (Voranigo).
